Identification Of Caveolin-1 As A Potential Causative Factor In The Generation Of Trastuzumab Resistance In Breast Cancer Cells

Journal of Cancer

Volumn 4, Issue 5, 2013, Pages 391-401

  Sekhar, Sreeja C ^a   Kasai, Tomonari ^a   Satoh, Ayano ^a   Shigehiro, Tsukasa ^a   Mizutani, Akifumi ^a   Murakami, Hiroshi ^a   El Aarag, Bishoy Ya ^b   Salomon, David S ^c   Massaguer, Anna ^d   de Llorens, Rafael ^d   Seno, Masaharu ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b Menoufia University   (Egypt)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF GIRONA   (Spain)

Author keywords

Antibody dependent cell mediated cytotoxicity (ADCC); Ec eGFP; ErbB2, Caveolin 1; Internalization; Trastuzumab.

Indexed keywords

CAVEOLIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LIGAND; PROTEIN TYROSINE KINASE; TRASTUZUMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BREAST CANCER; CANCER CELL; CAVEOLA; CONJUGATION; ENDOCYTOSIS; ENDOSOME; HUMAN; HUMAN CELL; PREDICTIVE VALUE; PROTEIN EXPRESSION;

EID: 84882959371     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.6470     Document Type: Article

References (49)

1. Lemmon MA, Schlessinger J. Cell signalling by receptor tyrosine kinases. Cell. 2010; 141: 1117-1134.
2. Sorkin A, Zastrow MV. Endocytosis and signalling: intertwining molecular networks. Nature reviews Molecular Cell Biology. 2009; 10: 609- 622
3. Hubbard R, Miller WT. Receptor tyrosine kinases: mechanisms of activation and signalling. Current Opinion in Cell Biology. 2007; 19: 117-123.
4. Bennasroune A, Gardin A, Aunis D, et al. Tyrosine kinase receptors as attractive targets of cancer therapy. Critical Reviews in Oncology/ Hematology. 2004; 50: 23-38.
5. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nature Reviews Cancer. 2009; 9: 463-475.
6. Hudziak R M, Lewis GD, Winget M, et al. p185HER2 monoclonal antibody has anti proliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Molecular Cell Biology. 1989; 9: 1165-1172.
7. Carter P, Presta L, Gorman CM, Ridgway JB, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. 1992; 89: 4285-4289.
8. Lane H A, Beuvink I, Motoyama A B, et al. ErbB2 Potentiates Breast Tumor Proliferation through Modulation of p27 Kip1-Cdk2 Complex Formation: Receptor Over expression Does Not Determine Growth Dependency. Molecular Cell Biology. 2000; 20: 3210- 3223.
9. Junttila TT, Akita RW, Parsons K, et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell. 2009; 15: 429-440.
10. Molina MA, Codony-servat J, Albanell J, et al. Trastuzumab (Herceptin), a Humanized Anti-HER2 Receptor Monoclonal Antibody, Inhibits Basal and Activated HER2 Ectodomain Cleavage in Breast Cancer Cells. Cancer Research. 2001; 61: 4744 -4749.
11. Peipp M, Dechant M, Valerius T. Effector mechanisms of therapeutic antibodies against ErbB receptors. Current Opinion in Immunology. 2008; 20: 436-443.
12. Arnould L, Gelly M, Penault-Llorca F, et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? British Journal of Cancer. 2006; 94: 259- 67.
13. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nature Medicine. 2000; 6: 443-6.
14. Birtwistle MR, Hatakeyama M, Yumoto N B, et al. Ligand-dependent responses of the ErbB signaling network: experimental and modeling analyses. Molecular Systems Biology. 2007; 3: 144.
15. Sorkin A, Goh LK. Endocytosis and intracellular trafficking of ErbBs. Experimental Cell Research. 2009; 315: 683- 696.
16. Baulida J, Kraus MH, Alimandi M, et al. All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. The Journal of Biological Chemistry. 1996; 271: 5251-7.
17. Roepstorff K, Grøvdal L, Grandal M, et al. Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer. Histochemistry and Cell Biology. 2008; 129: 563-578.
18. Shen F, Lin Q, Childress C, Yang W. Identification of the domain in ErbB2 that restricts ligand-induced degradation. Cellular Signalling. 2008; 20: 779- 86.
19. Hommelgaard AM, Lerdrup M, Deurs BV. Association with Membrane Protrusions Makes ErbB2 an Internalization-resistant Receptor. Molecular Biology of the Cell. 2004; 15: 1557-1567.
20. Haslekås C, Breen K, Pedersen KW, et al. The Inhibitory Effect of ErbB2 on Epidermal Growth Factor-induced Formation of Clathrin-coated Pits Correlates with Retention of Epidermal Growth Factor Receptor-ErbB2 Oligomeric Complexes at the Plasma Membrane. Molecular Biology of the Cell. 2005; 16: 5832-5842.
21. Sigismund S, Woelk T, Puri C, et al. Clathrin-independent endocytosis of ubiquitinated cargos. Proc. Natl. Acad. Sci. 2005; 102: 2760-2765.
22. Schlessinger J. Dimerization and activation of EGF receptor. Cell. 2002; 110: 669-672.
23. Nagy P, Vereb G, Sebestyén Z, et al. Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2. Journal of Cell Science. 2002; 115: 4251-4262.
24. Nagy P, Claus J, Jovin TM, Arndt Jovin DJ. Distribution of resting and ligand-bound ErbB1 and ErbB2 receptor tyrosine kinases in living cells using number and brightness analysis. Proc. Natl. Acad. Sci. 2010; 107: 16524-16529.
25. Kirkham M, Parton RG. Clathrin-independent endocytosis: New insights into caveolae and non-caveolar lipid raft carriers. Biochimica et Biophysica Acta (BBA)-Biomembranes. 2005; 1746: 350-363.
26. Pust S, Klokk TI, Musa N, et al. Flotillins as regulators of ErbB2 levels in breast cancer. Oncogene. 2012;: 1-9.
27. Austin CD, Mazie AM, Pisacane PI, et al. Endocytosis and Sorting of ErbB2 and the Site of Action of Cancer Therapeutics Trastuzumab and Geldanamycin. Molecular Biology of the Cell. 2004; 15: 5268-5282.
28. Hommelgaard AM, Roepstorff K, Vilhardt F. Caveolae: stable membrane domains with a potential for internalization. Traffic. 2005; 6: 720-4.
29. Römer W, Pontani LL, Sorre B, et al. Actin dynamics drive membrane reorganization and scission in clathrin-independent endocytosis. Cell. 2010; 140: 540-53.
30. Verma P, Ostermeyer-fay AG, Brown DA. Caveolin-1 Induces Formation of Membrane Tubules That Sense Actomyosin Tension and Are Inhibited by Polymerase I and Transcript Release Factor/Cavin-1. Molecular Biology of Cell. 2010; 21: 2226-2240.
31. Quest AFG, Gutierrez-Pajares J, Torres VA. Caveolin-1: an ambiguous partner in cell signalling and cancer. Journal of Cellular and Molecular Medicine. 2008; 12: 1130-50.
32. Engelman JA, Lee RJ, Karnezis A, et al. Reciprocal Regulation of Neu Tyrosine Kinase Activity and Caveolin-1 Protein Expression in Vitro and in Vivo. The Journal of Biological Chemistry. 1998; 273: 20448-20455.
33. Pero SC, Shukla GS, Armstrong AL, et al. Identification of a small peptide that inhibits the phosphorylation of ErbB2 and proliferation of ErbB2 overexpressing breast cancer cells. International Journal of Cancer. 2004; 111: 951-60.
34. Hashizume T, Fukuda T, Nagaoka T, et al. Cell type dependent endocytic internalization of ErbB2 with an artificial peptide ligand that binds to ErbB2. Cell Biology International. 2008; 32: 814 -26.
35. Vaidyanath A, Hashizume T, Nagaoka T, et al. Enhanced internalization of ErbB2 in SK-BR-3 cells with multivalent forms of an artificial ligand. Journal of Cellular and Molecular Medicine. 2011; 15: 2525-38.
36. Barr DJ, Ostermeyer-Fay AG, Matundan RA, Brown DA. Clathrin-independent endocytosis of ErbB2 in geldanamycin-treated human breast cancer cells. Journal of Cell Science. 2008; 121: 3155-66.
37. Pelkmans L, Bürli T, Zerial M, Helenius A. Caveolin-stabilized membrane domains as multifunctional transport and sorting devices in endocytic membrane traffic. Cell. 2004; 118: 767-780.
38. Liebl D, Difato F, et al. Mouse Polyomavirus Enters Early Endosomes, Requires Their Acidic pH for Productive Infection, and Meets Transferrin Cargo in Rab11-Positive Endosomes. Journal of Virology. 2006; 80: 4610-4622.
39. De LC, Cozzolino R, et al. Biological properties of a human compact anti-ErbB2 antibody. Carcinogenesis. 2005; 26: 1890- 1895.
40. Nabi IR, Le PU. Caveolae/raft-dependent endocytosis. The Journal of Cell Biology. 2003; 161: 673-7.
41. Xu W, Mimnaugh E, Rosser MF, et al. Sensitivity of mature ErbB2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. The Journal of Biological Chemistry. 2001; 276: 3702-8.
42. Pedersen NM, Madshus IH, Haslekås C, Stang E. Geldanamycin- induced down-regulation of ErbB2 from the plasma membrane is clathrin dependent but proteasomal activity independent. Molecular Cancer Research. 2008; 6: 1-500.
43. Williams TM, Lisanti MP. The caveolin proteins. Genome Biology. 2004; 3: 1-8.
44. Hino M, Doihara H, Kobayashi K, et al. Caveolin-1 as tumor suppressor gene in breast cancer. Surgery Today. 2003; 33: 486-90.
45. Lee SW, Reimer CL, Phil Oh, et al. Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene.1998; 16: 1391-1397.
46. Sagara Y, Mimori K, Yoshinaga K, et al. Clinical significance of Caveolin- 1, Caveolin-2 and HER2/neu mRNA expression in human breast cancer. British journal of Cancer. 2004; 91: 959-965.
47. Park SS, Kim JE, Kim YA, et al. Caveolin-1 is down-regulated and inversely correlated with HER2 and EGFR expression status in invasive ductal carcinoma of the breast. Histopathology. 2005; 47: 625-630.
48. Patani N, Martin LA, Reis-Filho JS, Dowsett M. The role of caveolin-1 in human breast cancer. Breast Cancer Research and Treatment. 2012; 131: 1-15.
49. Sloan E K, Ciocca DR, Pouliot N, et al. Stromal cell expression of caveolin- 1 predicts outcome in breast cancer. The American Journal of Pathology. 2009; 174: 2035-43